Table 1.
Currently available DAAs and drugs covered for payment under the medical care benefits in Korea
| Direct acting antivirals (DAA) | KMFD approved* | Drugs covered for payment under the medical care benefit** | 2017 KASL guideline*** |
|---|---|---|---|
| Ledipasvir/sofosbuvir (LED/SOF) | Yes | GT1a, GT1b with RAS, decompensated LC , post-LT | GT1b, GT1a, GT4, GT5, GT6 |
| Sofosbuvir (SOF) | Yes | Comined with ribavirin, PR or DCV | Refer to below |
| Daclatasvir (DCV) | Yes | DCV+ASV in GT1b, DCV+SOF in GT3, DCV+SOF in GT1a, GT1b with RAS, GT1 with decomp. LC, post LT | DCV+ASV in GT1b, DCV+SOF in GT1-GT6, DCV+SOF in decompensated LC & post-LT |
| Aunaprevir (ASV) | Yes | DCV+ASV in GT1b | DCV+ASV in GT1b |
| Ombitasvir/paritaprevir/ritonavir (OPr) | Yes | OPrD in GT1, OPr in GT4† | OPrD in GT1, OPr in GT4† |
| Dasabuvir (D) | Yes | OPrD in GT1, OPr in GT4† | OPrD in GT1, OPr in GT4† |
| Elbasvir/grazoprevir (EBR/GZP) | Yes | GT1a, GT1b, GT4† | GT1a, GT1b, GT4† |
| Glecaprevir/pibrentasvir (G/P) | Expected to be approved | Not yet | GT1-6‡ |
| Sofosbuvir/velpatasvir (SOF/VEL) | No | None | GT1-6‡ |
| Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) | No | None | GT1-6 with DAA failure†† |
| TN & TE GT3 with LC | |||
| Peg-interferon with ribavirin (PR) | Yes | GT1-3 | GT2, 3, 5, 6, for whom DAA is not indicated |
| Sof+ribavirin | Yes | GT2, 4 | GT2 |
| Sof+PR | Yes | GT1, GT4 | Not recommended |
KMFD, Korean Ministry of Food and Drug Safety; HIRA, Health Insurance Review and Assessment service.
Approved state in DEC. 2017, may change during the publication, please refer to website (www.mfds.go.kr) for further information;
Refundable by medical insurance, may change during the publication, please refer to website (www.hira.or.kr) for further information;
Indicated in 2017 KASL HCV guideline, may differ from medicare covered drug, please refer to website (www.kasl.org) for further information including ribavirin combination and treatment duration;
May differ from each patient with presence or absence of treatment experience, liver cirrhosis or RAS in terms of adding ribavirin, treatment duration;
Treatment duration may differ from each genotype, presence or absence of treatment experinece or cirrhosis, please refer to website (www.kasl.org) for further information include ribavirin combination and treatment duration;
Treatment indication may differ from each types of DAA failure, please refer to website (www.kasl.org) for further information include ribavirin combination and treatment duration.